Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease
Terry J. Smith
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. Supplement_1, pp. S13-S26
Open Access | Times Cited: 22

Showing 22 citing articles:

Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
Raymond S. Douglas, Steven M. Couch, Sara T. Wester, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 109, Iss. 1, pp. 25-35
Open Access | Times Cited: 27
Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease
Petros Perros, Miloš Žarković, Simon H. S. Pearce, et al.
American Journal of Ophthalmology (2023) Vol. 252, pp. 94-100
Open Access | Times Cited: 13
Thyroid-associated ophthalmopathy: the role of oxidative stress
Chao Ma, Haoyu Li, Shuwen Lu, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 4
Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management
Anna Scarabosio, Pier Luigi Surico, Rohan Bir Singh, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 776-776
Open Access | Times Cited: 4
Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis
Huang Wenxin, Xiaodan Ou, Shinn-Zong Lin, et al.
Endocrine Practice (2025)
Closed Access
Role of biomarkers in South Indian Thyroid Eye Disease study (SITED)
Pratheeba Devi Nivean, Rohit Shetty, Swaminathan Sethu, et al.
Orbit (2025), pp. 1-9
Open Access
Evaluating the performance of ChatGPT in patient consultation and image-based preliminary diagnosis in thyroid eye disease
Yue Wang, Shuo Yang, Chengcheng Zeng, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Can chimeric antigen receptors – based therapy bring a gleam of hope for thyroid-associated ophthalmopathy and other autoimmune diseases?
Wei‐Yi Zhou, Xinyu Zhu, Yongquan Shi
Medical Review (2025)
Closed Access
Teprotumumab in thyroid eye disease: wonder drug or great divider?
Petros Perros, László Hegedűs
European Thyroid Journal (2023) Vol. 12, Iss. 4
Open Access | Times Cited: 10
How patients experience thyroid eye disease
Terry J. Smith, László Hegedűs, Ira M. Lesser, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 9
Interdisziplinäre Therapie der Erkrankungen der Orbita
Anja Eckstein, Hans‐Jürgen Welkoborsky
Laryngo-Rhino-Otologie (2024) Vol. 103, Iss. S 01, pp. S43-S99
Open Access | Times Cited: 2
“Effectiveness of Different Treatment Modalities in Initial and Chronic Phases of Thyroid Eye Disease: A Systematic Review with Meta-analysis”
J.M. Alves, Wanderley Marques Bernardo, Danilo Villagelin
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 11, pp. 2997-3009
Open Access | Times Cited: 2
Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review
Brooke E. Bocklud, Waddih Fakhre, Brennan Murphy, et al.
Cureus (2023)
Open Access | Times Cited: 2
Aktuelle Therapieansätze der Endokrinen Orbitopathie – Sind die zielgerichteten Therapien die Zukunft?
Anja Eckstein, Mareile Stöhr, Gina-Eva Görtz, et al.
Klinische Monatsblätter für Augenheilkunde (2023) Vol. 241, Iss. 01, pp. 48-68
Closed Access | Times Cited: 2
A TSHR-Targeting Aptamer in Monocytes Correlating with Clinical Activity in TAO
Jiamin Cao, Feng Zhang, Haiyan Chen, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 3577-3588
Open Access
CD20 + T lymphocytes in isolated Hashimoto’s thyroiditis and type 3 autoimmune polyendocrine syndrome: a pilot study
Ilaria Stramazzo, Giorgio Mangino, Silvia Capriello, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 11, pp. 2865-2871
Open Access
Role of regulatory T cells in pathogenesis and therapeutics of Graves’ disease and Graves’ orbitopathy
Daniela Gallo, Nataša Kuštrimović, Eliana Piantanida, et al.
Elsevier eBooks (2024), pp. 471-484
Closed Access
Fat-suppression T2 relaxation time and water fraction predict response to intravenous glucocorticoid therapy for thyroid-associated ophthalmopathy
Linhan Zhai, Feng Li, Ban Luo, et al.
European Radiology (2024)
Closed Access
Intraocular and extraocular manifestations of thyroid dysfunction in Danish patients – A Nationwide Study
Lena Boulakh
Acta Ophthalmologica (2024) Vol. 102, Iss. S283, pp. 3-25
Open Access
Farmaci biologici per l’orbitopatia basedowiana: recenti sviluppi tra realtà e speranze
Daniela Gallo, Maria Laura Tanda, Luigi Bartalena
L Endocrinologo (2024) Vol. 25, Iss. 6, pp. 605-613
Closed Access
Teprotumumab’s Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis
Nicholas Householder, Coby Ray
touchREVIEWS in Endocrinology (2024) Vol. 20, Iss. 2
Open Access
Endokrine Orbitopathie
Anja Eckstein, Michael Oeverhaus, Lars Möller, et al.
Springer Reference Medizin (2024), pp. 1-21
Closed Access
Page 1

Scroll to top